tbuckley/cabot-search huggingface dataset:
Line Omission Distorts Meaning
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMES HOPE (1801-1841)
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of itching in atopic eczema.
Journal: BMJ (1989)

The nature of the relation between multiple sclerosis and vitamin B12 deficiency in these cases is unclear; as it might, however, offer a clue to the understanding of an obscure neurological disease4 and as vitamin B12 is widely prescribed as a placebo in multiple sclerosis it seems to be an association worth more detailed investigation.I would there- fore be grateful to hear of any further examples from your readers.
General Anesthesia
Authors: Casimir Harris, Urban H. Eversole
Journal: New England Journal of Medicine (1947)

THE purpose of this paper is to summarize the progress in general anesthesia since the publication of a similar report in 1943.1 The subject is presented under the following headings: the development of anesthesiology as a specialty, the growing importance of curare, the expanded usefulness of Pentothal Sodium, new technics and physiologic investigations.Development of the Specialty of AnesthesiologyAt this writing, there are approximately three hundred physicians certified by the American Board of Anesthesiology in the United States, and there are over two thousand members of the American Society of Anesthesiologists. Yet the current News Letter of the Society . . .
High incidence of repeat catheterization and revascularization in patients with normal stress myocardial perfusion SPECT early after PCI Sean W. Hayes, Howard C. Lewin, Enrique F. Schisterman, Ishac Cohen, Raluca D. Agafitei, John D. Friedman, Daniel S. Berman. Cedars-Sinai Medical Center, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
Food and Character.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin’s Lymphoma: Final Results of the German Hodgkin’s Lymphoma Study Group Trial HD5
Authors: Markus Sieber, Hans Tesch, Beate Pfistner, Ulrich Rueffer, Bernd Lathan, Oana Brosteanu, Ursula Paulus, Tina Koch, Michael Pfreundschuh, Markus Loeffler, Andreas Engert, Andreas Josting, Jürgen Wolf, Dirk Hasenclever, Jeremy Franklin, Eckhart Duehmke, Axel Georgii, Klaus-Peter Schalk, Hartmut Kirchner, Gottfried Doelken, Reinhold Munker, Peter Koch, Richard Herrmann, Richard Greil, Anna Paola Anselmo, Volker Diehl
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To investigate whether treatment results in intermediate-stage Hodgkin’s lymphoma can be improved by rapid application of non–cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP), doxorubicin, bleomycin, and vinblastine (ABV), and ifosfamide, methotrexate, etoposide, and prednisone (IMEP), repeated every 6 weeks, was compared with conventional alternating COPP/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) administered every 8 weeks. PATIENTS AND METHODS: From January 1988 to January 1993, 996 patients in stage I or II Hodgkin’s lymphoma with at least one risk factor (massive mediastinal tumor, massive spleen involvement, extranodal disease, elevated ESR, or more than two lymph node areas involved) and all patients in stage IIIA Hodgkin’s lymphoma were randomized to receive two cycles of COPP/ABVD or COPP/ABV/IMEP followed by extended-field radiotherapy. RESULTS: Both regimens produced similar rates for treatment responses (complete remission, 93% v 94%), freedom from treatment failure (80% v 79%), and overall survival (88% for both regimens) at a median follow-up time of 7 years. Most serious toxicities during chemotherapy were similar in both regimens. However, World Health Organization grade 3 and 4 leukocytopenia occurred significantly more frequently in the COPP/ABV/IMEP arm (53% v 44% of patients; P = .010). There were no differences in the number of serious infections and toxic deaths during therapy. The number of second malignancies was also the same in both arms (22 each). CONCLUSION: Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin’s lymphoma and produce excellent long-term treatment results.
Infant AIDS prevention study finally gets going
Authors: P. Cotton
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2014)

Treatment of Hepatitis C in Patients With HIV Coinfection 353Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV is challenging.In a multicenter, open-label, and nonrandomized trial that enrolled 223 patients concurrently infected with HCV and HIV, Sulkowski and colleagues found that combination treatment with sofosbuvir and ribavirin was associated with high rates of sustained virologic response.In an Editorial, Saag discusses advances in treating patients with HCV and HIV coinfection.
Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
Authors: Seung-Yong Jeong, David B. Chessin, Deborah Schrag, Elyn Riedel, W. Douglas Wong, Jose G. Guillem
Journal: JNCI Journal of the National Cancer Institute (2005)

Stages II and III of the newly revised tumor-node-metastasis staging system for colon cancer (American Joint Committee on Cancer [AJCC] Staging Manual sixth edition) differ from those in the fi fth edition ( 1 ) .In the sixth edition, stage II is subdivided into IIa (T3N0) and IIb (T4N0) and stage III is subdivided into IIIa (T1 -2N1M0), IIIb (T3 -4N1M0), and IIIc (anyTN2M0).This stratifi ed grouping was motivated by the large difference in survival between stage II and III patients noted in the analysis of the National Cancer Data Base registry by Greene et al. ( 2 ) and recognition that having a T4 tumor could have a greater impact on prognosis than regional lymph node involvement ( 3 ) .Recently, O'Connell et al. ( 4 ) reported survival of 119 363 colon cancer patients from the Surveillance, Epidemiology, and End Results (SEER) program and demonstrated that survival was worse for the subset of patients with stage IIb (T4N0M0) than for those with stage IIIa (T1 -2N1M0) tumors.The authors attributed this paradoxical survival difference to several potential factors: 1) preferential administration of chemotherapy for stage IIIa patients; 2) understaging of T4N1 tumors as T4N0, thereby resulting in migration of aggressive disease from stage IIIb to stage IIb; 3) greater likelihood of a curative en bloc surgical resection for stage IIIa; and 4) a relative disproportional increase of biologically more aggressive tumors in stage IIb.However, because the SEER
Mesenteric vasodilator responses in cirrhotic rats: A role for nitric oxide
Authors: R MATHIE
Journal: Hepatology (1996)

The contribution of nitric oxide to mesenteric arterial vasodilator responses was investigated in the isolated perfused mesenteric arterial bed of cirrhotic rats (carbon tetrachloride/phenobarbitone; n = 6). Age- matched (n = 9) and phenobarbitone-treated rats (n = 9) served as controls. Responses to the endothelium-dependent dilators acetylcholine and adenosine 5′-triphosphate (ATP) and the smooth muscle dilator (NO donor) sodium nitroprusside were investigated after tone was raised by continuous infusion of methoxamine, before and during infusion of the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 30 μmol/L) ± L-arginine (1 mmol/L). A significant hyporesponsiveness to methoxamine infusion in cirrhotic preparations (P < .05) was not fully corrected by L-NAME. There was no difference in the percentage vasodilator response to acetylcholine in the cirrhotic group compared with controls; L-NAME significantly and reversibly inhibited the dilator response in all groups. ATP elicited dose-dependent vasodilation that, in the absence of L-NAME, did not differ between the groups. By contrast, in the presence of L-NAME, ATP (5 × 10-8 mol) produced pronounced, reversible vasoconstriction only in cirrhotic animals (P < .02). Vasodilatation attributable to sodium nitroprusside (5 × 10-8 mol) was significantly attenuated in cirrhotic rats. The methoxamine data support the concept of mesenteric hyposensitivity to vasoconstrictor agents in cirrhosis that may be at least partly NO mediated. Increased NO activity in smooth muscle leading to decreased guanylate cyclase availability may account for the diminished vasodilator responses to sodium nitroprusside in cirrhotic preparations. The unchanged responsiveness to vasodilatation by acetylcholine (ACh) and the vasoconstriction to ATP observed during NO blockade in cirrhotic animals indicate that mesenteric endothelial NO is unchanged or possibly diminished.
CRIPPLED CHILDREN.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Carl Thiersch (1822-1895), Leipzig surgeon
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT0253 Efficacy and safety of leflunomide therapy in lupus nephritis:a meta-analysis
Authors: Q Ren, H Zeng
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To evaluate the efficacy and safety of leflunomide in treating lupus nephritis (LN). <h3>Methods</h3> According to the requirements of meta-analysis, a literature search about efficacy and safety of leflunomide therapy in LN was performed among Cochrane clinical controlled trials database, PubMed, BMJ-Clinical Evidence, CNKI, VIP and Wanfang data from the establishment of the database till December 2010.All included RCTs were graded in term of randomization, allocation concealment and blinding and non-RCTs were graded in term of grouping method, blinding, withdrawal and loss of follow-up, baseline comparability, diagnostic criteria and bias control. RevMan 5.0 software was used for meta-analysis. <h3>Results</h3> A total of 828 literatures were included. Five RCTs and 2 non-RCTs were enrolled for meta-analysis.Leflunomide group was treated with leflunomide and glucocorticoid, while control group was given cyclophosphamide and glucocorticoid or placebo. The 24 h urine protein, SCr and SLEDAI scores of leflunomide group were significantly lower than that of cyclophosphamide group. There was no significant difference in C3,positive rate of anti-ds DNA between leflunomide group and cyclophosphamide group. There was no significant difference in infection, herpes zoster,hypertension, palpitations, leukopenia, alopecial, elevation in ALT, memoxenia, rashes, or the incidence of gastrointestinal reactions between the two groups. <h3>Conclusions</h3> Based on the current evidence, the efficacy and safety of leflunomide for treatment of LN are close to cyclophosphamide. Further evidence from RCT studies is needed to elucidate the efficacy and safety of leflunomide for LN. <h3>Disclosure of Interest</h3> None declared
Hyperventilation in children.
Journal: BMJ (1968)

BRITIsH__ 255 long dependence on replacement therapy with steroids and possibly with thyroid and sex hormones as well.It is not yet possible to predict which patients are going to retain vision as a result of pituitary ablation.The lesions most likely to be affected are microaneurysms, venous irregularities, new vessel formation, and retinal, preretinal, and vitreous haemorrhages.Proliferation of connective tissue usually continues though perhaps at a slower rate.Postoperative reduction of excessive retinal capillary permeability and opening up of areas of capillary closure has been shown by fluorescein angiography.1'These changes are frequently unaccompanied by improved vision, but useful vision may be retained.In addition to effects on the retinal circulation glomerular capillary abnormalities may regress"5 and proteinuria diminish, but despite this the renal blood flow and glomerular filtration rate fall even in those with initially good renal function.1 Neuropathy and arterial disease appear to be unaffected.It is easier to define the contraindications for treatment than the indications.Ophthalmological contraindications include bilateral severe macular damage, retinal detachment, and preretinal lesions such as extensive fibrosis.Luft's1 early studies showed that pituitary ablation was poorly tolerated by the elderly and by those with heart disease, hypertension, neuropathy with postural hypotension, and severe renal disease.Many workers now also stipulate that patients treated should be less than 40 years old, should have at least two-thirds normal renal function, and should be free of chronic infection.Patients unlikely to cope with complex hormone replacement therapy should also be excluded.These restrictions eliminate three out of four potential subjects for pituitary ablation.Most patients selected for treatment have relatively advanced retinopathy, with either useful vision lost in one eye or both eyes threatened by vascular lesions in the macula region.The results of treatment might be better if it was given at an earlier stage of the disease, but the potential morbidity and mortality of the procedure make it an unattractive proposition to someone with good vision in both eyes.The available evidence suggests that pituitary ablation halts visual deterioration in from 20 to 40% of patients who would not have improved spontaneously.Many patients going blind will be prepared to chance the benefits and accept the risks, but they should be made aware of both.
Incorrect Description in Table
Authors: Simon Erridge
Journal: JAMA Surgery (2016)

John W. Scott, MD, MPH; Olubode A. Olufajo, MD, MPH; Gabriel A. Brat, MD; John A. Rose, MD, MPH; Cheryl K. Zogg, MSPH, MHS; Adil H. Haider, MD, MPH; Ali Salim, MD; Joaquim M. Havens, MD
Inhibition of Protein Synthesis in Brain and Learning and Memory Following Puromycin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver
Authors: P Ballmer
Journal: Hepatology (1996)

Albumin and fibrinogen synthesis rates were measured in 15 subjects with different clinical stages of postviral cirrhosis and compared with galactose elimination capacity and aminopyrin breath test. Forty-three mg per kg body weight [2H5ring]phenylalanine with an isotopic enrichment of 10 atom% were intravenously injected. [2H5ring]phenylalanine enrichments in the plasma-free phenylalanine and the albumin and fibrinogen isolates were measured by gas chromatography-mass spectrometry. Fractional synthesis rates of albumin were normal in Child A cirrhosis (7.6 ± 2.2%d), but were lower in both Child B (3.5 ± 0.8%d) and C (4.5 ± 2.8%d). Absolute rates of albumin synthesis were (103 ± 30 mg/kg/d) in the child A group and substantially lower in the Child B (50 ± 3 mg/kg/d) and C (36 ± 20 mg/kg/d) group. The average fractional synthesis rate of fibrinogen was 16.7 ± 7.5%d and the absolute synthesis rate 11.6 ± 6.4 mg/kg/d. The values of the galactose elimination capacity and the aminopyrin breath test were below the normal range in all patients, gradually decreasing with an increase in the severity of the clinical stage of cirrhosis. Albumin synthesis rates significantly correlated with the Child scores, the galactose elimination capacity, and the aminopyrin breath test, whereas fibrinogen synthesis rates showed no such correlations.